Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of Trifluridine/Tipiracil (TAS102) in Combination With Nanoliposomal Irinotecan (NAL-IRI) in Advanced GI Cancers

NCT03368963 is registered in ClinicalTrials.gov with Emory University as lead sponsor.

NCT NCT03368963
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03368963 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of Trifluridine/Tipiracil (TAS102) in Combination With Nanoliposomal Irinotecan (NAL-IRI) in Advanced GI Cancers
Lead sponsor
Emory University
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
January 30, 2018
Completion date
November 28, 2025
Enrollment
64 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal adenocarcinoma, gastric adenocarcinoma, metastatic pancreatic adenocarcinoma, non-resectable cholangiocarcinoma, stage iii colorectal cancer, stage iii gastric cancer, stage iii pancreatic cancer, stage iv colorectal cancer, stage iv gastric cancer, stage iv pancreatic cancer, stage iva colorectal cancer, stage ivb colorectal cancer, unresectable digestive system adenocarcinoma, unresectable pancreatic carcinoma